These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 15525796

  • 1. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
    Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ.
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
    [Abstract] [Full Text] [Related]

  • 2. Application of oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) lipid conjugates as steric barrier molecules in liposomal formulations.
    Ansell SM, Kojic LD, Hankins JS, Sekirov L, Boey A, Lee DK, Bennett AR, Klimuk SK, Harasym TO, Dos Santos N, Semple SC.
    Bioconjug Chem; 1999 Mar; 10(4):653-66. PubMed ID: 10411464
    [Abstract] [Full Text] [Related]

  • 3. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes.
    Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T, Kiwada H.
    J Control Release; 2010 Mar 03; 142(2):160-6. PubMed ID: 19850094
    [Abstract] [Full Text] [Related]

  • 4. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH.
    Clin Cancer Res; 1999 Nov 03; 5(11):3645-52. PubMed ID: 10589782
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery.
    Heyes J, Hall K, Tailor V, Lenz R, MacLachlan I.
    J Control Release; 2006 May 15; 112(2):280-90. PubMed ID: 16603272
    [Abstract] [Full Text] [Related]

  • 6. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.
    Judge A, McClintock K, Phelps JR, Maclachlan I.
    Mol Ther; 2006 Feb 15; 13(2):328-37. PubMed ID: 16275098
    [Abstract] [Full Text] [Related]

  • 7. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose.
    Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, Corstens FH, Boerman OC.
    J Pharmacol Exp Ther; 2000 Jun 15; 293(3):996-1001. PubMed ID: 10869403
    [Abstract] [Full Text] [Related]

  • 8. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
    Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G.
    J Pharmacol Exp Ther; 2001 Aug 15; 298(2):607-12. PubMed ID: 11454922
    [Abstract] [Full Text] [Related]

  • 9. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C, Wang C, Yang H, Zhao X, Wei N, Cui J.
    J Pharm Pharmacol; 2012 Mar 15; 64(3):372-82. PubMed ID: 22309269
    [Abstract] [Full Text] [Related]

  • 10. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice.
    Ishida T, Ichikawa T, Ichihara M, Sadzuka Y, Kiwada H.
    J Control Release; 2004 Mar 24; 95(3):403-12. PubMed ID: 15023452
    [Abstract] [Full Text] [Related]

  • 11. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T, Atobe K, Wang X, Kiwada H.
    J Control Release; 2006 Oct 27; 115(3):251-8. PubMed ID: 17045355
    [Abstract] [Full Text] [Related]

  • 12. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
    Wilson KD, Raney SG, Sekirov L, Chikh G, deJong SD, Cullis PR, Tam YK.
    Int Immunopharmacol; 2007 Aug 27; 7(8):1064-75. PubMed ID: 17570323
    [Abstract] [Full Text] [Related]

  • 13. The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN.
    Raney SG, Wilson KD, Sekirov L, Chikh G, de Jong SD, Cullis PR, Tam YK.
    J Drug Target; 2008 Aug 27; 16(7):564-77. PubMed ID: 18686126
    [Abstract] [Full Text] [Related]

  • 14. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
    Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N.
    Int J Pharm; 2010 Jun 15; 392(1-2):218-23. PubMed ID: 20227473
    [Abstract] [Full Text] [Related]

  • 15. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
    Ishida T, Kiwada H.
    Int J Pharm; 2008 Apr 16; 354(1-2):56-62. PubMed ID: 18083313
    [Abstract] [Full Text] [Related]

  • 16. The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine.
    Wilson KD, de Jong SD, Kazem M, Lall R, Hope MJ, Cullis PR, Tam YK.
    J Gene Med; 2009 Jan 16; 11(1):14-25. PubMed ID: 19003796
    [Abstract] [Full Text] [Related]

  • 17. Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine.
    Holland JW, Hui C, Cullis PR, Madden TD.
    Biochemistry; 1996 Feb 27; 35(8):2618-24. PubMed ID: 8611565
    [Abstract] [Full Text] [Related]

  • 18. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
    Wang X, Ishida T, Kiwada H.
    J Control Release; 2007 Jun 04; 119(2):236-44. PubMed ID: 17399838
    [Abstract] [Full Text] [Related]

  • 19. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.
    Anticancer Res; 2009 Jun 04; 29(6):2111-20. PubMed ID: 19528471
    [Abstract] [Full Text] [Related]

  • 20. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
    Taguchi K, Urata Y, Anraku M, Watanabe H, Kadowaki D, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Maruyama T, Otagiri M.
    Drug Metab Dispos; 2009 Nov 04; 37(11):2197-203. PubMed ID: 19679674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.